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Background: The interplay between the novel adipokine retinol-binding protein-4 (RBP4) and coronary artery
disease (CAD) is still obscure. We investigated the relationship between RBP4 levels and the presence and severity
of angiographically proven CAD and determined its possible role in acute myocardial infarction (AMI).
Methods: 305 individuals with angiographically proven CAD (CAD-patients), were classified into 2 subgroups: 1)
acute myocardial infarction (AMI, n = 141), and 2) stable angina (SA, n = 164). Ninety-one age- and sex-matched
individuals without CAD, but with at least 2 classical cardiovascular risk factors, served as controls (non-CAD group). RBP4
serum levels were measured at hospital admission and were analyzed in relation to the coronary severity stenosis,
assessed by the Gensini-score and the number of coronary narrowed vessels. Other clinical parameters, including insulin
levels, HOMA-IR, hsCRP, glycaemic and lipid profile, and left-ventricular ejection fraction were also assessed.
Results: Serum RBP4 levels were significantly elevated in patients with CAD compared to non-CAD patients (39.29 ±
11.72 mg/L vs. 24.83 ± 11.27 mg/L, p < 0.001). We did not observe a significant difference in RBP4 levels between AMI
and SA subgroups (p = 0.734). Logistic regression analysis revealed an independent association of CAD presence with
serum RBP4 (β = 0.163, p = 0.006), and hsCRP (β = 0.122, p = 0.022) levels, in the whole study group. Among variables,
hsCRP (β = 0.220), HDL (β = −0.150), and RBP4 (β = 0.297), correlated in both univariate and multivariate analysis with
CAD severity (R2 = 0.422, p < 0.001). Similarly, RBP4 concentrations increased with the number of coronary narrowed
vessels (p < 0.05).
Conclusion: Patients with CAD, both SA and AMI, showed elevated RBP4 serum levels. Notably, increased RBP4
concentration seemed to independently correlate with CAD severity, but no with AMI.
Trial registration: The ClinicalTrials.gov Identifier is: NCT00636766
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Coronary artery disease (CAD) is the leading cause of
morbidity and mortality worldwide with the risk for
CAD development being higher among patients with
obesity, diabetes and other insulin resistant states. Nu-
merous studies have been previously conducted in order* Correspondence: vlambad@otenet.gr
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article, unless otherwise stated.to identify novel biomarkers indicating either the pres-
ence or the severity of CAD [1,2]. Such a precise cardio-
vascular risk assessment is crucial for the choice of
diagnostic methods and intensive therapeutic modalities
(e.g. coronary angiography) with obvious benefits and
risks [3]. Thus, the identification of new serum biomarkers
would add to the prognostic value of the traditional ones.
A growing body of evidence, the adipocyte-derived cy-
tokines, known as adipokines, seem to interfere with the
crosstalk between adipose tissue, insulin resistance and
CAD [4]. Retinol-Binding Protein-4 (RBP4), a novel adi-
pokine/hepatokine, initially identified by Yang et al. [5],tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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circulation. Most, but not all studies, have demonstrated
its link with insulin resistance and obesity [5-7]. Elevated
plasma RBP4 levels have been predominantly found in
men and women with abdominal adiposity even in the
non-diabetic state [8,9]. Similarly, high RBP4 levels in
obese children seem to be related to adipose tissue mass,
to the differentiation of adipocytes, and to multiple risk
factors for adiposity-related co-morbidities [10,11].
Accumulating data strongly support the association of
RBP4 circulating levels with traditional, (e.g. dyslipidae-
mia, hypertension, albuminuria) and non-traditional car-
diovascular risk factors (e.g. cytokines) mainly through
the impairment of glucose and lipid metabolism and adi-
pose tissue dysfunction, despite that opposite findings
put RBP4 changes in dispute [12-14]. Although, the in-
volvement of RBP4 in the development of subclinical
atherosclerosis has been proven [15], its prognostic value
in carotid [16] or coronary [17] atherosclerosis progres-
sion is still obscure. This raises the question whether cir-
culating RBP4 concentrations could serve as a CAD
predictor. Regarding the aforementioned inconsistent
interplay of RBP-4 with diabetes and obesity, it becomes
more valuable to assess RBP4 levels among diabetic and
non-diabetic cohorts.
In this study, we sought to investigate the relationship
between RBP4 levels and the presence and severity of
angiographically proven CAD, and to determine its pos-
sible role in acute myocardial infarction (AMI).
Methods
Study population
We initially identified 868 individuals who underwent
coronary angiography from January to June 2012 in
“Attikon” University Hospital of Athens, Greece. We
then excluded patients with history of recent, −within
the past 6 months- severe chronic heart failure (class
NYHA II - IV), malignant diseases, major trauma or
surgery, severe renal (creatinine > 2 mg/dl) or liver in-
sufficiency (ALT > 2 times upper normal limit), acute
or chronic infectious disease, or any kind of immune-
mediated disease. Among individuals undergoing coronary
angiography, 305 patients with significant, angiographic-
ally proven CAD, defined as stenosis of more than 50% of
the luminal diameter in a major epicardial coronary vessel,
were assigned to the CAD-group. Based on clinical and la-
boratory findings, the latter group was further subdivided
into the following subgroups:
1) AMI (n = 141): Patients consecutively hospitalized in
the coronary care unit of our department with acute
myocardial infarction (AMI) (STEMI, NSTEMI)
within 12 hours of symptoms onset. The AMI
diagnosis was made on the basis of typicalsymptoms consistent with myocardial ischemia
(chest discomfort or anginal equivalent) that
continued for >30 min, newly developed ischemic
ST-T changes (ST-elevation or ST-segment depression
or prominent T-wave inversion) in at least 2
contiguous ECG leads, and elevated cardiac-associated
biomarkers of necrosis in an appropriate clinical
setting.
2) SA (n = 164): Consecutive patients with stable
angina (SA) diagnosed as: chest pain or angina-
equivalent on exertion, signs of myocardial ischemia
on functional testing (myocardial perfusion scintigraphy,
stress echocardiography, exercise electrocardiography)
and established CAD defined as previous myocardial
infarction or percutaneous coronary intervention or
coronary artery bypass graft. We excluded patients
with unstable angina, such as those with recent onset
of cardiac-origin symptoms or angina at rest and
normal levels of cardiac troponin.
Among the remaining individuals without angiographic-
ally proven CAD, we selected a cohort of 91 individuals,
age- and sex-matched to CAD group. That group had at
least 2 cardiovascular risk factors (diabetes, dyslipidemia,
hypertension, obesity, positive family history for early
CAD), but no clinical evidence of CAD, and served as
control (non-CAD group). The main purpose to set such
selection criteria in the control group was to limit con-
founders and create more comparable groups.
The medical history of all participants was comprehen-
sively recorded, and a clinical examination, electrocardio-
gram (ECG), trans-thoracic echocardiography and blood
sampling, were carried out before angiography. The study
complied with the Declaration of Helsinki, and the trial
protocol was approved by the local Ethics Committee.
Written informed consent was obtained from all pa-
tients before entering the study.
Clinical and echocardiographic examination
At the time of a clinical examination, body mass index
(BMI, calculated as weight (kg) / height (m)2), waist-hip
ratio (WHR), blood pressure, were determined. Waist
circumference was assessed at the level midway between
the lower rib margin and the iliac crest. The hips were
measured at the level of the greater femoral trochanters.
Thus, WHR expressed waist circumference divided by hip
girth. BP was measured twice, after keeping all partici-
pants in a sitting position for 15 minutes. There was a
5 minute interval between the two measurements and the
mean value was estimated for study purposes. Medica-
tions, co-morbidities and smoking history were assessed
through a structured questionnaire preceding clinical
examination. Before angiography, we also obtained the
patients’ regular prescribed medications, based on
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considered present if a patient was treated with insulin or
oral agents or had a fasting glucose level ≥126 mg/dl
(7.0 mmol/L), HbA1c ≥6.5% or a known history of dia-
betes. Hypertension was defined by systolic blood pres-
sure ≥140 mmHg, diastolic blood pressure ≥90 mmHg,
the current use of antihypertensive treatment, or a
combination of the 3. Dyslipidemia was defined as
non-HDL levels ≥190 mg/dl, the current use of lipid-
lowering treatment, or both [18]. Echocardiographic
examination (Vivid 7; General Electric, Ohio, OH,
USA) was performed in all participants by the same
operator in order to evaluate left ventricular morph-
ology and systolic function.
Coronary angiography
All participants underwent coronary angiography by ex-
perienced cardiologists. Coronary artery severity was
assessed using the number of narrowed vessels (>50%)
Gensini score, which is derived from the co-evaluation
of the number of stenotic coronary artery segments, the
degree of their lumen stenosis and the localization of
stenotic change [4]. The Gensini score was given as 1
for 1–25% narrowing, 2 for 26–50% narrowing, 4 for
51–75% narrowing, 8 for 76–90% narrowing, 16 for 91–
99% narrowing and 32 for total occlusion. The score is
then multiplied by a factor that takes into account the
importance of the lesion's position in the coronary arter-
ial tree, for example, 5 for the left main coronary artery,
2.5 for the proximal left anterior descending coronary
artery (LAD) or proximal left circumflex coronary artery
(LCX), 1.5 for the mid-region of the LAD, 1.5 for prox-
imal and mid-region RCA, and 1 for the distal LAD,
mid-distal region of the LCX and RCA. The average
score for all the coronary arteries expressed Gensini
score [4].
Blood analyses
In patients with AMI, blood samples were drawn on ad-
mission and before treatment initiation to assess inflam-
matory markers. The rest of biochemical parameters,
such as lipids and glycaemic indexes (fasting plasma glu-
cose – FPG, glycosylated haemoglobin – HbA1c) were
assayed after an overnight fast at least 24 h after admis-
sion. Similarly, venous blood samples were collected fol-
lowing an overnight fasting, in the rest of groups (SA
and non-CAD). Glucose and lipids were analysed enzy-
matically (Chemwell 2910; Awareness Technology Inc,
Palm City, Fl, USA). Low density lipoprotein cholesterol
(LDL-C) was calculated by Friedewald formula. The
intra-assay coefficients of variation (CVs) for total chol-
esterol, triglycerides, HDL and FPG were: 0.84%, 0.4%,
1.57% and 0.6%, respectively. In parallel, the inter-assay
CVs for the abovementioned parameters were 1.3%,1.3%, 2.00%, and 1.6%, respectively. The HbA1c was de-
termined by high-performance liquid chromatography
(Menarini Diagnostics, Florence, Italy) in the diabetic
subpopulation. A white blood cells (WBC) count analysis
was performed using Cell Dyne 1700 electronic counter
(Sequoia-Turner Corporation, Santa Clara, CA, USA),
with 1.99% intra-assay CV and 1.92% inter-assay CV.
To measure insulin and RBP4, serum was separated
from the blood corpuscles by centrifugation at 5000 g
for 10 min and kept frozen at −80°C until the analysis.
We quantified serum insulin with IRMA kit (DIAsource
ImmunoAssays S.A., Louvain-la-Neuve, Belgium). The
inter- and intra-assay CVs were 6.3% and 2%, respect-
ively. Insulin resistance was calculated by a homeostasis-
model-assessment (HOMA-IR) index with the following
formula: HOMA-IR = fasting insulin (mU/L) × FPG
(mg/dl)/405. Using a commercially available enzyme im-
munoassay kit, we assayed serum concentrations of
RBP4 (Immunodiagnostik AG, Bensheim, Germany).
The intra-assay CV was 9.7% and the inter-assay CV
was 5%. Measurement of high-sensitivity CRP (hsCRP)
was performed using a particle enhanced immunoturbi-
dimetric assay (Hitachi 917 analyser; Boehringer Mann-
heim, Germany). The detection limit was 0.1 mg/L, with
intra- and inter-assay CVs of 1.34% and 5.7%, respect-
ively. All serum concentrations (triplicate determina-
tions) were analysed in a blinded manner with respect
to any clinical information.
Statistical methods
Results are presented as mean values ± standard devi-
ation (SD). Normality of distribution was assessed with
Kolmogorov-Smirnov test. We used student’s t-test and
chi-square for comparison of parametric and non-
parametric variables between CAD versus non-CAD
group and AMI versus SA subgroup. Comparison across
all cohorts (AMI, SA and non-CAD) was performed by
one-way ANOVA and post-hoc Tuckey analysis. The re-
lationships of RBP4 with other variables and CAD sever-
ity indexes were evaluated with Pearson correlation and
standard multiple regression analysis. We explored the
independent determinants of CAD in the whole study
group using logistic regression analysis and the re-
ceiver operating characteristic (ROC) curve. A two-tailed
p value <0.05 was considered to be statistically significant.
We used the computer statistical software package SPSS
(version 17.0; SPSS Inc, Chicago, IL, USA).
Results
Clinical and biochemical variables
The clinical and laboratory characteristics of the whole
study cohort and CAD subgroups are presented in
Tables 1 & 2, respectively. Between CAD and non-CAD
groups we observed significant (p < 0.05) differences in
Table 1 Clinical and biochemical parameters,
angiographic findings and echocardiographic estimation






Males, n (%) 269 (88.20) 74 (81.32) 0.229
Age (y) 64 ± 13 62 ± 11 0.563
Smoking, n (%) 149 (48.85) 23 (25.27) <0.001
Hypertension, n (%) 195 (63.93) 61 (67.03) 0.109
Dyslipidemia, n (%) 253 (82.95) 61 (67.03) 0.049
Diabetes, n (%) 74 (24.26) 16 (17.58) 0.184
Medications
Statins, n (%) 159 (52.13) 25 (27.47) <0.001
Fibrates, n (%) 6 (1.97) 2 (2.2) 0.902
ACEIs/ARBs, n (%) 152 (49.83) 48 (52.75) 0.891
Anti-platelets, n (%) 178 (58.36) 15 (16.48) <0.001
BMI (kg/m2) 28.93 ± 4.60 27.71 ± 4.22 0.088
WHR 0.97 ± 0.11 0.95 ± 0.09 0.133
SBP (mmHg) 145 ± 23 130 ± 17 <0.001
DBP (mmHg) 81 ± 13 80 ± 12 0.310
TChol (mg/dl) 193 ± 46 201 ± 52 0.401
HDL-C (mg/dl) 44 ± 13 48 ± 13 <0.001
LDL-C (mg/dl) 121 ± 43 128 ± 43 0.398
TG (mg/dl) 142 ± 77 132 ± 66 0.280
FPG (mg/dl) 135 ± 67 120 ± 25 0.045
HbA1c (%)* 7.7 ± 1.1 7.1 ± 0.9 0.020
Insulin (mU/L) 15.03 ± 8.71 9.01 ± 4.73 0.004
HOMA-IR 5.01 ± 2.45 2.67 ± 0.72 0.001
WBC (cells/μL) 9489 ± 3384 6826 ± 1858 <0.001
hsCRP (mg/L) 9.24 ± 3.16 2.97 ± 1.28 <0.001
RBP-4 (mg/L) 39.29 ± 11.72 24.83 ± 11.27 <0.001
LVEF (%) 54 ± 9 58 ± 9 0.009
Angiography
1-vessel 126 (41.31) - -
2-vessels 131 (42.95) - -
3-/4-vessels 48 (15.74) - -
Data are expressed as means ± SD. n, number of patients; ACEIs,
Angiotensin-converting enzyme inhibitors; ARBs, Angiotensin II Receptor
Blockers; BMI, body-mass index; WHR, waist-hip ratio; SBP, systolic blood
pressure, DBP, diastolic blood pressure; TChol, total cholesterol; TG, triglycerides;
FPG, fasting plasma glucose; HOMA-IR, homeostasis model assessment; WBC,
white blood cells; hsCRP, high-sensitivity CRP; LVEF, left ventricular
ejection fraction.
*HbA1c was measured only in the diabetic subgroup.
Table 2 Clinical and biochemical parameters,
angiographic findings and echocardiographic estimation






Males, n (%) 114 (80.85) 150 (91.46) 0.541
Age (y) 63 ± 13 66 ± 10 0.204
Smoking, n (%) 94 (66.67) 55 (33.54) <0.001
Hypertension, n (%) 93 (65.96) 102 (62.20) 0.702
Dyslipidemia, n (%) 106 (75.18) 147 (89.63) 0.403
Diabetes, n (%) 27 (19.14) 47 (28.66) 0.113
Medications
Statins, n (%) 28 (19.86) 141 (85.97) <0.001
Fibrates, n (%) 3 (2.13) 3 (1.83) 0.799
ACEIs/ARBs, n (%) 59 (41.84) 86 (52.44) 0.188
Anti-platelets, n (%) 20 (14.18) 158 (96.34) <0.001
BMI (kg/m2) 28.29 ± 4.43 29.48 ± 5.03 0.085
WHR 0.97 ± 0.11 0.98 ± 0.09 0.356
SBP (mmHg) 149 ± 24 141 ± 19 0.018
DBP (mmHg) 84 ± 14 78 ± 11 0.007
TChol (mg/dl) 210 ± 47 178 ± 42 0.038
HDL-C (mg/dl) 44 ± 12 45 ± 13 0.942
LDL-C (mg/dl) 141 ± 44 104 ± 36 <0.001
TG (mg/dl) 125 ± 45 145 ± 83 0.082
FPG (mg/dl) 148 ± 70 124 ± 55 0.032
HbA1c (%)* 8.1 ± 1.3 7.6 ± 1.2 0.048
Insulin (mU/L) 15.26 ± 4.97 14.83 ± 5.12 0.861
HOMA-IR 5.58 ± 2.04 4.54 ± 1.95 0.223
WBC (cells/μL) 9912 ± 3526 8117 ± 2515 <0.001
hsCRP (mg/L) 13.04 ± 5.68 5.97 ± 1.03 <0.001
RBP-4 (mg/L) 37.83 ± 17.34 38.76 ± 11.36 0.734
LVEF (%) 54 ± 8 55 ± 9 0.531
Angiography
1-vessel 71 (50.35) 51 (31.09) 0.205
2-vessels 38 (26.95) 55 (33.54) 0.743
3-/4-vessels 32 (22.70) 58 (35.37) 0.063
Data are expressed as means ± SD. AMI, acute myocardial infarction; SA, stable
angina; n, number of patients; ACEIs, Angiotensin-converting enzyme inhibitors;
ARBs, Angiotensin II Receptor Blockers; BMI, body-mass index; SBP, systolic blood
pressure, DBP, diastolic blood pressure; TChol, total cholesterol; TG, triglycerides;
FPG, fasting plasma glucose; HOMA-IR, homeostasis model assessment; WBC,
white blood cells; hsCRP, high-sensitivity CRP; LVEF, left ventricular
ejection fraction.
*HbA1c was measured only in the diabetic subgroup.
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HDL, WBC, insulin resistance and hsCRP levels. Sub-
group analysis showed that most of the aforementioned
differences between CAD and non-CAD groups were
predominantly driven by the acute phase of AMI sub-
group. Thereby, those differences disappeared betweenSA and non-CAD patients (p > 0.05), except WBC and
hsCRP. As expected, CAD group had higher prescription
rate of statins and anti-platelet agents compared to non-
CAD (p < 0.001).
The AMI subgroup showed higher smoking rate (p <
0.001), SBP (p = 0.018) and DBP (p = 0.007) levels
Lambadiari et al. Cardiovascular Diabetology 2014, 13:121 Page 5 of 8
http://www.cardiab.com/content/13/1/121compared to SA subgroup. Regarding medications, we
observed lower usage of statins (p < 0.001) and anti-
platelet agents (p < 0.001) in AMI that SA subgroup
before angiography. Notably, no patient was receiving
vitamin supplements, which might have affected our
results. As long as it concerns biochemical parameters,
AMI-patients appeared with worse lipid profile and in-
creased levels of FPG, HbA1c, WBC and hsCRP than
the SA subgroup (p < 0.05).
Significantly higher RBP4 values were found in CAD
rather than non-CAD patients (p < 0.001). Importantly,
RBP4 concentrations did not differ between AMI and
SA subgroups (p = 0.734). However, both AMI and SA
subgroups showed considerably upregulated RBP4 con-
centrations than non-CAD group (p = 0.010, p < 0.001,
respectively) (Tables 1 & 2). Further subgroup analysis
did not reveal any influence of gender, diabetes or sta-
tins’ usage on RBP4 levels within both CAD and non-
CAD groups (p > 0.05).
Correlations
We searched for correlations of RBP4 with the rest of
variables within the CAD group. In univariate analysis,
RBP4 significantly correlated with hsCRP, fasting insulin
and HOMA-IR. All those correlations remained signifi-
cant in multivariate analysis (hsCRP: β = 0.190, p = 0.037;
fasting insulin: β = 0.331, p < 0.001; HOMA-IR: β = 0.326,
p < 0.001) (R2 = 0.380, p < 0.001).
In univariate analysis, the severity of CAD, quantified
by the Gensini score, was significantly correlated with
FPG, HOMA-IR, hsCRP, HDL and RBP4 (p < 0.05). The
latter variables entered standard multiple regression ana-
lysis (Table 3). Among variables, hsCRP, HDL and RBP4
remained as independent determinants of the Gensini
score (R2 = 0.422, p < 0.001). In addition to this, RBP4
levels significantly increased across the number of dis-
eased vessels from 34.19 ± 17.3 mg/L (1-vessel group) to
41.56 ± 16.32 mg/L (2-vessels group) and 49.19 ±
17.3 mg/L (3-/or 4-vessels group) (p < 0.05). In case of
hsCRP, we found significant difference between 1-vessel
and 3-/or 4-vessels group (7.02 ± 2.18 mg/dl vs 12.57 ±
3.99 mg/dl, p = 0.011). On the other hand, HDL levelsTable 3 Standard multiple regression analysis of Gensini
score (dependent variable) and other independent
variables
Gensini score
β 95% CI P value
RBP4 0.297 0.028 – 0.587 0.012
HDL-C −0.150 −0.205 – 0.001 0.040
FPG 0.121 −0.002 – 0.303 0.269
HOMA-IR 0.038 −0.042 – 0.059 0.745
hsCRP 0.220 0.006 – 0.370 0.004did not significantly change across the number of nar-
rowed vessels.
Multiple logistic regression analysis was performed in the
whole study group to estimate the association of significant
CAD presence with clinical and biochemical variables, after
adjustment for traditional cardiovascular risk factors
like diabetes, hypertension, dyslipidemia, smoking and
male gender. The presence of significant CAD was
independently associated with serum RBP4 (β = 0.163,
p = 0.006), and hsCRP (β = 0.122, p = 0.022) levels. The
ROC curves of RBP4 and hsCRP for the discrimination
between CAD or not are shown in Figure 1. Using
ROC analysis, the area under the curve (AUC) was
0.719 (95% CI 0.632-0.805, p < 0.001) for RBP4 and
0.649 (95% CI 0.561-0.736, p = 0.005) for hsCRP.
Discussion
The present cross-sectional study demonstrated in-
creased serum RBP4 levels in patients with CAD (either
AMI or SA) compared to age- and sex-matched individ-
uals without CAD, but with at least 2 classical cardiovas-
cular risk factors. In our study cohort, the presence of
significant CAD was independently related to RBP4 and
hsCRP circulating levels. This is the first study demon-
strating the independent association of RBP4 with CAD
severity indexes (e.g. Gensini score and number of
narrowed vessels).
In spite of the rather established relation to insulin
resistance and cardiovascular risk factors, the actual as-
sociation of RBP4 levels with atherosclerotic-related
cardiovascular disease is still controversial. Previous
studies have shown the positive association of RBP4 with
subclinical atherosclerosis [19-21]. In elderly men, RBP4
levels correlated with hypertriglyceridemia and prior
cerebrovascular disease [22]. Furthermore, plasma RBP4
concentration proved to be related to the presence of
cardiovascular disease in non-obese, non-diabetic sub-
jects [23]. A recent prospective trial suggested its value
in predicting CAD in a large women cohort during a
follow-up period of 9 to 16 years [24]. In contrast, an-
other large prospective trial doubted the additive prog-
nostic value of RBP4 among CAD-free men and women
[17]. Further recent studies in experimental models of
high cardiovascular risk in humans have actually exhib-
ited a protective role of RBP4 in vasculature [25,26], or
even reduced levels in men with AMI [27], which add to
the controversy concerning the actual role of RBP4 in
atherosclerosis. However, in these studies the samples
are smaller, they mainly include men, and do not distin-
guish between subjects according to the actual vessel
pathology but rather according to cardiovascular risk. In
our study cohort, consisting of patients with SA, AMI
and non-CAD subjects, RBP4 and hsCRP levels were in-
dependently associated with the presence of significant
Figure 1 Receiver operating characteristic curve analysis of Retinol-Binding Protein-4 (RBP4) (blue line) and hsCRP (green line) as
markers for the diagnosis of coronary artery disease (CAD).
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had at least two cardiovascular risk factors, presented
with high suspicion of CAD. Thus, this is the first study
implicating the potential of serum RBP4 levels in dis-
criminating patients with established CAD from high
risk patients, using coronary angiographic criteria. Not-
ably, the presence of AMI did not affect RBP4 serum
levels among CAD patients, implicating the dissociation
of RBP4 from acute coronary event. Perhaps, circulating
RBP4 is predominantly influenced by the presence of
coronary atherosclerotic lesions rather than the athero-
sclerotic plaque destabilization. However, this postula-
tion needs further investigation.
Accumulating data support the relationship of novel
adipokines with CAD severity [28]. To our knowledge
this is the first study indicating the association of CAD se-
verity, expressed by Gensini score, with RBP4 levels in
addition to hsCRP and HDL. Interestingly, RBP4 levels
significantly increased across the number of diseased
vessels. Those striking findings suggest an interaction
between RBP4 and the pathophysiological process of
coronary atherosclerosis. The latter notion has been re-
cently supported by the higher RBP4 expression in epi-
cardial fat derived from CAD rather than non-CAD
patients [29]. Those authors hypothesized higher pro-
tein released in close proximity to coronary arteries, im-
plying a causative role in the pathogenesis of coronary
atherosclerosis. Perhaps, measuring serum RBP4 could
contribute to patients’ risk stratification in order to
avoid diagnostic procedure that bares risks itself, suchas coronary angiography. Unambiguously, future trials
will clarify the emerging role of serum RBP4 as a valid
biomarker of CAD extent.
Regarding the underlying mechanisms, we observed the
independent correlation of RBP4 with insulin resistance
indices and established markers of inflammation, like
hsCRP. More recently, RBP4 levels independently pre-
dicted early endothelial dysfunction, linking adipose tissue
inflammation and subclinical atherosclerosis in non-
diabetic individuals [30]. The association of RBP4 with
markers of inflammation is supported by several studies.
RBP4 was found to induce in vitro inflammation in endo-
thelial cells, by stimulating expression of proinflammatory
molecules, such as vascular cell adhesion molecule 1
(VCAM-1), E-selectin, intercellular adhesion molecule 1
(ICAM-1), monocyte chemoattractant protein 1 (MCP-1),
and interleukin-6 (IL-6) [31]. Those effects may be medi-
ated via the activation of NADPH oxidase and NF-κB lead-
ing to endothelial inflammation. In another study involving
patients with diabetes and CAD, RBP4 levels rose in sub-
jects with both conditions, and were rather correlated with
TNFa than with markers of insulin resistance [32].
The role of retinoids in lipid metabolism is well known
and is mediated through the regulation of ApoC-III and
VLDL production and fatty acid oxidation [33]. A rela-
tively large study of patients with type 2 diabetes or
CAD previously reported the relation of RBP4 levels to
an unfavorable lipid profile [34]. In the diabetic state, a
positive association of RBP4 with plasma triglycerides
levels and VLDL-apoB100 total fractional catabolic rate
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potential interaction between RBP4 and CAD through
pro-atherogenic lipoproteins and their enzymes. More-
over, RBP4 has been recently identified as an HDL-
associated protein; it is demonstrated that in patients
with acute coronary syndrome, HDL shifts to an inflam-
matory profile, which can in turn, alter the protective ef-
fects of HDL on the atherosclerotic plaque. Thus, in this
inflammatory milieu, RBP4 could also share such prop-
erties [36]. In parallel, RBP4 has exhibited modest herit-
ability and sexual dimorphism (higher levels in men)
[37], while it is considered to represent a link between
visceral adiposity and cardiovascular disease [9]. Taken
together, our study failed to reveal any association of
RBP4 with lipids, gender or BMI. Perhaps, the lipid-
lowering medications, the low percentage of women and
the vast majority of overweight, but non-obese partici-
pants, might have confounded the relationship of the
above parameters, respectively, with RBP4 levels.
The major limitation of the present investigation was
the cross-sectional design, which prevented us from in-
ferring cause-effect relationship of RBP4 with CAD. Al-
though we did not recognise differences between acute
and stable condition of CAD, the cross-sectional design
of our study did not allow us to evaluate the association
of RBP4 with either AMI occurrence or long-term clinical
outcomes. Since the majority of patients with classical car-
diovascular risk factors (e.g. diabetes, dyslipidemia, hyper-
tension etc.) were already treated, we cannot rule out the
plausible effects of pharmaceutical agents (e.g. statins) on
RBP4, leading to underestimation of its predictive power.
Another important limitation was the considerable diffe-
rences in some biochemical parameters between CAD
and non-CAD groups, which might have affected RBP4
fluctuations. Despite the independent association between
RBP4CAD and CAD diagnosis, the absence of matching
for baseline characteristics may weaken our conclusions.
Finally, as our control group sample comprised of patients
with cardiovascular risk factors, we couldn’t extrapolate
our conclusions to healthy subjects. Another study limita-
tion is the potential influence of the transthyretin TTR-
RBP4 complex in the affinity towards RBP4 that could be
interfering with the ELISA measurement of RBP4. How-
ever, a previous study has shown that circulating RBP4
and TTR were not affected by human obesity or T2DM,
compared to lean controls [38]. The same could apply to
our population as well, considering that a low grade in-
flammation often coexists with T2DM and obesity and
that in our study we did not recognize differences between
acute and stable condition of CAD.
Conclusion
In conclusion, the present study documented RBP4 being
a strong predictor of CAD, defined as angiographicallysignificant coronary stenosis. That result was not influ-
enced by acute (AMI) or stable (SA) CAD phase. Most
importantly, RBP4 levels seemed to independently correl-
ate to CAD severity. Thus, RBP4 could be a cost-effective,
easy to obtain, novel risk biomarker, that could contribute
to improved clinical decision making and management of
patients at risk of CAD.
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